Efficacy and Safety of Remdesivir in Adult Solid Organ Transplant Recipients: A Scoping Review

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Jun 27

PMID 38931432

Authors

Catherine Smith

Maria Eugenia Novara

Andrea Cona

Anna Dolcimascolo

Giulia Cancellieri

Francesca Mortillaro

Enrico Ottavio Giannini

Anna Carollo

Alessandra Mularoni

Alessio Provenzani

Affiliations

Soon will be listed here.

Abstract

The SARS-CoV-2 infection has been associated with important mortality, particularly in immunocompromised patients, including solid organ transplant (SOT) recipients. Remdesivir (RDV) is an antiviral drug that has proven to be effective in reducing the replication of the virus in host cells, by which it may reduce the progression of symptoms and, consequently, the length of hospital stay and mortality. Randomized controlled trials have evaluated its use in the general population but never in SOT recipients. For the first time in this review, the safety and efficacy of RDV is evaluated in this specific population. The literature research was conducted using PubMed/MEDLINE and Scopus databases from 1 January 2020 to 24 November 2023, and 23 studies were analyzed. Although no clinical studies specifically evaluating this population have been conducted yet, RDV is likely safe for SOT patients when compared to the general population, so prescribers should consider utilizing RDV in SOT patients who are at high risk for progression to severe COVID-19. Future research will allow for the confirmation of the observed results and the acquisition of broader and clearer data regarding the safety and efficacy of the drug in this specific setting.

References

Trapani S, Masiero L, Puoti F, Rota M, Del Manso M, Lombardini L . Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: A nationwide population-based study. Am J Transplant. 2020; 21(7):2509-2521. PMC: 9906464. DOI: 10.1111/ajt.16428. View

Estiverne C, Strohbehn I, Mithani Z, Hirsch J, Wanchoo R, Goyal P . Remdesivir in Patients With Estimated GFR <30 ml/min per 1.73 m or on Renal Replacement Therapy. Kidney Int Rep. 2020; 6(3):835-838. PMC: 7694470. DOI: 10.1016/j.ekir.2020.11.025. View

Tricco A, Lillie E, Zarin W, OBrien K, Colquhoun H, Levac D . PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018; 169(7):467-473. DOI: 10.7326/M18-0850. View

Lee T, Murthy S, Del Corpo O, Senecal J, Butler-Laporte G, Sohani Z . Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clin Microbiol Infect. 2022; 28(9):1203-1210. PMC: 9117160. DOI: 10.1016/j.cmi.2022.04.018. View

Black C, Termanini K, Aguirre O, Hawksworth J, Sosin M . Solid organ transplantation in the 21 century. Ann Transl Med. 2018; 6(20):409. PMC: 6230860. DOI: 10.21037/atm.2018.09.68. View

Colaneri M, Amarasinghe N, Rezzonico L, Pieri T, Segalini E, Sambo M . Early remdesivir to prevent severe COVID-19 in recipients of solid organ transplant: a real-life study from Northern Italy. Int J Infect Dis. 2022; 121:157-160. PMC: 9076039. DOI: 10.1016/j.ijid.2022.05.001. View

Shafiekhani M, Shahabinezhad F, Niknam T, Tara S, Haem E, Mardani P . Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand?. Virol J. 2021; 18(1):228. PMC: 8607221. DOI: 10.1186/s12985-021-01700-2. View

Heldman M, Kates O, Safa K, Kotton C, Georgia S, Steinbrink J . Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemic. Am J Transplant. 2021; 22(1):279-288. PMC: 8653312. DOI: 10.1111/ajt.16840. View

Wang G, Xiao B, Deng J, Gong L, Li Y, Li J . The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy. Front Pharmacol. 2022; 13:791922. PMC: 8847594. DOI: 10.3389/fphar.2022.791922. View

10.

Mohseni M, Albus M, Kaminski A, Harrison M . A Case of COVID-19 Re-Infection in a Liver Transplant Patient. Cureus. 2021; 13(5):e14916. PMC: 8186344. DOI: 10.7759/cureus.14916. View

11.

Meshram H, Kute V, Patel H, Banerjee S, Navadiya V, Desai S . Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation. Transpl Infect Dis. 2021; 23(4):e13629. PMC: 8209918. DOI: 10.1111/tid.13629. View

12.

Jamir I, Lohia P, Pande R, Setia R, Singhal A, Chaudhary A . Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. Ann Hepatobiliary Pancreat Surg. 2020; 24(4):526-532. PMC: 7691211. DOI: 10.14701/ahbps.2020.24.4.526. View

13.

Zimmermann J, Glueck O, Fertmann J, Sienel W, Yavuz G, Damirov F . COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies. Transplant Proc. 2022; 54(6):1504-1516. PMC: 8743506. DOI: 10.1016/j.transproceed.2021.12.014. View

14.

Wong C, Au I, Cheng W, Man K, Lau K, Mak L . Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study. Aliment Pharmacol Ther. 2022; 56(1):121-130. PMC: 9111503. DOI: 10.1111/apt.16894. View

15.

Yi S, Rogers A, Saharia A, Aoun M, Faour R, Abdelrahim M . Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center. Transplantation. 2020; 104(11):2208-2214. PMC: 7302089. DOI: 10.1097/TP.0000000000003339. View

16.

Andre E, Lemaitre F, Verdier M, Haufroid V, Pinto Pereira J, Hantson P . Transient Lactic Acidosis and Elevation of Transaminases after the Introduction of Remdesivir in a Patient with Acute Kidney Injury. Case Rep Crit Care. 2024; 2024:6631866. PMC: 10904205. DOI: 10.1155/2024/6631866. View

17.

Takashita E, Yamayoshi S, Fukushi S, Suzuki T, Maeda K, Sakai-Tagawa Y . Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75. N Engl J Med. 2022; 387(13):1236-1238. PMC: 9511631. DOI: 10.1056/NEJMc2209952. View

18.

Glueck O, Liang X, Badell I, Wratil P, Graf A, Krebs S . Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS-CoV-2 in the early phase after transplantation. Infection. 2023; 52(3):847-855. PMC: 11143031. DOI: 10.1007/s15010-023-02116-6. View

19.

Biscarini S, Villa S, Genovese C, Tomasello M, Tonizzo A, Fava M . Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study. Biomedicines. 2022; 10(8). PMC: 9405567. DOI: 10.3390/biomedicines10082002. View

20.

Lim J, Park S, Jeon Y, Chung Y, Kwon J, Jeon Y . Clinical Effectiveness and Safety of Remdesivir in Hemodialysis Patients with COVID-19. Kidney Int Rep. 2022; 7(11):2522-2525. PMC: 9462925. DOI: 10.1016/j.ekir.2022.08.031. View